AIMLogo.jpg
Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”
November 08, 2016 08:30 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted an article from Corporate America News magazine, released on...
Hemispherx Updates the Status of the Alferon® Manufacturing Facility
July 11, 2016 08:30 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, July 11, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) in response to various questions about the status of the work to repair damage to our Alferon®...
AIMLogo.jpg
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)
January 20, 2016 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has...
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
October 19, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey
August 27, 2015 08:30 ET | AIM ImmunoTech Inc.
NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the...
AIMLogo.jpg
Hemispherx Biopharma Reminder Regarding Stockholder Open House at Manufacturing and Research Facility in New Jersey
August 19, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 19, 2015 (GLOBE NEWSWIRE) -- As previously announced and provided in the proxy materials, the Management and the Board of Directors of Hemispherx Biopharma (NYSE MKT:HEB) will host...
AIMLogo.jpg
Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection(R)
August 17, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that as the Company works toward the re-launch of Alferon N, it has...
AIMLogo.jpg
Hemispherx Expands Its Collaboration With Emerge Health for the Commercialization of Alferon in Australia and New Zealand
August 11, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
AIMLogo.jpg
Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection(R) for Treatment of Middle East Respiratory Syndrome (MERS)
July 15, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that they have submitted an application for orphan drug designation...
AIMLogo.jpg
Hemispherx to Present at the Marcum Microcap Conference in New York
May 20, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...